{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:09:31Z","timestamp":1791234571325,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007154","name":"Wake Forest University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007154","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by unregulated red blood cell production resulting in elevated hemoglobin and\/or hematocrit levels. Patients often have symptoms such as fatigue, pruritus, and painful splenomegaly, but are also at risk of thrombosis, both venous and arterial. Ruxolitinib, a selective Janus kinase inhibitor, is approved by the US Food and Drug Administration as second-line cytoreductive treatment after intolerance or inadequate response to hydroxyurea. Although ruxolitinib has been widely used in this setting, limited data exist in the literature on ruxolitinib treatment patterns and outcomes among patients with PV in routine clinical practice. We report a retrospective, observational, cohort study of patients treated for PV with ruxolitinib across three US centers (academic and regional practice) from December 2014-December 2019. The study included 69 patients, with a median follow-up duration of 3.7 years (95% CI, 2.9\u20134.4). Our data demonstrate very high rates of hematocrit control (88% of patients by three months and 89% by six months); few patients required dose adjustments or suspension. No arterial thromboses were observed; however, the follow-up duration does not allow for the generation of meaningful conclusions from this. Three patients had thrombotic events; one was in the setting of a second malignancy, one post-operative, and a third related to prolonged immobility. We also found that 28% of patients initiated ruxolitinib as a result of poorly controlled platelet counts, second only to hydroxyurea intolerance (46%) as a reason to start therapy. In clinical practice, ruxolitinib continues to be effective in controlling hematocrit levels after three and six months of treatment in patients and is associated with low thrombotic risk.<\/jats:p>","DOI":"10.1007\/s00277-024-05735-7","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:01:21Z","timestamp":1714003281000},"page":"2837-2843","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2841-8321","authenticated-orcid":false,"given":"Aleksander","family":"Chojecki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2319-3573","authenticated-orcid":false,"given":"Danielle","family":"Boselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Dortilus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issam","family":"Hamadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Begley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupali","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Podoltsev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole Baranda","family":"Balmaceda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulraheem","family":"Yacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Gregory","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany Knick","family":"Ragon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilay Arvind","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasa Reddy","family":"Sanikommu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Symanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5407-9875","authenticated-orcid":false,"given":"Michael Richard","family":"Grunwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"issue":"1","key":"5735_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00428-022-03480-8","volume":"482","author":"U Gianelli","year":"2023","unstructured":"Gianelli U, Thiele J, Orazi A, Gangat N, Vannucchi AM, Tefferi A, Kvasnicka HM (2023) International Consensus classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms. Virchows Arch 482(1):53\u201368. https:\/\/doi.org\/10.1007\/s00428-022-03480-8","journal-title":"Virchows Arch"},{"issue":"33","key":"5735_CR2","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1200\/jco.2012.42.3863","volume":"30","author":"RM Emanuel","year":"2012","unstructured":"Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F et al (2012) Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 30(33):4098\u20134103. https:\/\/doi.org\/10.1200\/jco.2012.42.3863","journal-title":"J Clin Oncol"},{"issue":"9","key":"5735_CR3","doi-asserted-by":"publisher","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","volume":"123","author":"Gruppo Italiano Studio Policitemia","year":"1995","unstructured":"Gruppo Italiano Studio Policitemia (1995) Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 123(9):656\u2013664. https:\/\/doi.org\/10.7326\/0003-4819-123-9-199511010-00003","journal-title":"Ann Intern Med"},{"issue":"5","key":"5735_CR4","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00277-019-03625-x","volume":"98","author":"M Griesshammer","year":"2019","unstructured":"Griesshammer M, Kiladjian J-J, Besses C (2019) Thromboembolic events in polycythemia vera. Ann Hematol 98(5):1071\u20131082. https:\/\/doi.org\/10.1007\/s00277-019-03625-x","journal-title":"Ann Hematol"},{"issue":"9","key":"5735_CR5","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A et al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27(9):1874\u20131881. https:\/\/doi.org\/10.1038\/leu.2013.163","journal-title":"Leukemia"},{"issue":"5","key":"5735_CR6","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R et al (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32(5):1057\u20131069. https:\/\/doi.org\/10.1038\/s41375-018-0077-1","journal-title":"Leukemia"},{"issue":"5","key":"5735_CR7","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R et al (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(5):426\u2013435. https:\/\/doi.org\/10.1056\/NEJMoa1409002","journal-title":"N Engl J Med"},{"issue":"3","key":"5735_CR8","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1016\/s2352-3026(19)30207-8","volume":"7","author":"JJ Kiladjian","year":"2020","unstructured":"Kiladjian JJ, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, Mesa R, Miller CB, Passamonti F, Durrant S et al (2020) Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol 7(3):e226\u2013e237. https:\/\/doi.org\/10.1016\/s2352-3026(19)30207-8","journal-title":"Lancet Haematol"},{"issue":"10","key":"5735_CR9","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.clml.2020.05.019","volume":"20","author":"A Coltoff","year":"2020","unstructured":"Coltoff A, Mesa R, Gotlib J, Shulman J, Rampal RK, Siwoski O, Yacoub A, Moliterno A, Yang A, Braunstein E et al (2020) Real-world outcomes of ruxolitinib treatment for polycythemia vera. Clin Lymphoma Myeloma Leuk 20(10):697\u2013703e691. https:\/\/doi.org\/10.1016\/j.clml.2020.05.019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"13","key":"5735_CR10","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1002\/cncr.34195","volume":"128","author":"A Alvarez-Larr\u00e1n","year":"2022","unstructured":"Alvarez-Larr\u00e1n A, Garrote M, Ferrer-Mar\u00edn F, P\u00e9rez-Encinas M, Mata-Vazquez MI, Bellosillo B, Arellano-Rodrigo E, G\u00f3mez M, Garc\u00eda R, Garc\u00eda-Guti\u00e9rrez V et al (2022) Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance\/intolerance to hydroxyurea. Cancer 128(13):2441\u20132448. https:\/\/doi.org\/10.1002\/cncr.34195","journal-title":"Cancer"},{"issue":"11","key":"5735_CR11","doi-asserted-by":"publisher","first-page":"e915","DOI":"10.1016\/j.clml.2021.06.023","volume":"21","author":"I Altomare","year":"2021","unstructured":"Altomare I, Parasuraman S, Paranagama D, Kish J, Lord K, Yu J, Colucci P (2021) Real-world dosing patterns of ruxolitinib in patients with polycythemia vera who are resistant to or intolerant of hydroxyurea. Clin Lymphoma Myeloma Leuk 21(11):e915\u2013e921. https:\/\/doi.org\/10.1016\/j.clml.2021.06.023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"5735_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/s1470-2045(16)30558-7","volume":"18","author":"F Passamonti","year":"2017","unstructured":"Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, Callum J, Vannucchi AM, Sivgin S, Bensasson C et al (2017) Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol 18(1):88\u201399. https:\/\/doi.org\/10.1016\/s1470-2045(16)30558-7","journal-title":"Lancet Oncol"},{"issue":"6","key":"5735_CR13","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s00277-022-04815-w","volume":"101","author":"S Pepe","year":"2022","unstructured":"Pepe S, Rossi E, Trawinska M, Tatarelli C, Di Veroli A, Maurillo L, Romano A, Crescenzi SL, di Toritto TC, Tafuri A et al (2022) Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group. Ann Hematol 101(6):1275\u20131282. https:\/\/doi.org\/10.1007\/s00277-022-04815-w","journal-title":"Ann Hematol"},{"key":"5735_CR14","doi-asserted-by":"publisher","first-page":"106629","DOI":"10.1016\/j.leukres.2021.106629","volume":"109","author":"D Tremblay","year":"2021","unstructured":"Tremblay D, Ronner L, Podoltsev N, Gotlib J, Heaney M, Kuykendall A, O\u2019Connell C, Shammo JM, Fleischman A, Mesa R et al (2021) Ruxolitinib discontinuation in polycythemia vera: patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. Leuk Res 109:106629. https:\/\/doi.org\/10.1016\/j.leukres.2021.106629","journal-title":"Leuk Res"},{"issue":"8","key":"5735_CR15","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa2308809","volume":"390","author":"M Kremyanskaya","year":"2024","unstructured":"Kremyanskaya M, Kuykendall AT, Pemmaraju N, Ritchie EK, Gotlib J, Gerds A, Palmer J, Pettit K, Nath UK, Yacoub A et al (2024) Rusfertide, a hepcidin mimetic, for control of erythrocytosis in polycythemia vera. N Engl J Med 390(8):723\u2013735. https:\/\/doi.org\/10.1056\/NEJMoa2308809","journal-title":"N Engl J Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05735-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05735-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05735-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T02:06:15Z","timestamp":1722045975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05735-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5735"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05735-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3867334\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]},"assertion":[{"value":"15 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The following relevant COI: Support for the present manuscript provided by Incyte as institutional support\/ research funding, Grant number I-Rux-16-67Other disclosures directly or indirectly related to this work but reported by authors per Springer editorial policies include the following: Consulting Fees and Honoraria: Constellation Pharmaceuticals, AbbVie, Amgen, Astellas, Blueprint Medicines, Bristol Myers Squibb, Cardinal Health, CTI BioPharma, Daiichi Sankyo, Gamida Cell, Genentech, Gilead, GSK\/Sierra Oncology, Incyte, Invitae, Jazz, Karius, Novartis, Ono Pharmaceutical, Pfizer, Pharmacosmos, Premier, Servier\/Agios, and Stemline TherapeuticsPayment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Incyte, Research to Practice, Novartis, Sierra Oncology, Genentech, Sierra, Blueprint, Geron, Telios, CTI Biopharma, Incyte, BMS, Abbvie, Glaxo Smith Kline, Morphosys, Gilead, AstraZeneca, Cogen Biosciences, Abbvie, Janssen Oncology, Epizyme -honoraria or speakers bureau--Of note -- No writing support by Incyte for this manuscriptParticipation on a Data Safety Monitoring Board or Advisory Board: Novartis, Pfizer, Incyte, CTI, PharmaAstellas, Apellis, Gilead, Notable Labs, Celgene, AbbVie, Pfizer, Celgene\/BMS, Jazz, Incyte, Agios, Servier, Boehringer-Ingelheim, Novartis, Astellas, Daiichi Sankyo, Geron, Taiho, Seattle Genetics, BeyondSpring, Takeda, Ionis, Amgen, Janssen, Roche, Genentech, Epizyme, Syndax, Gilead, Kura, Chiesi, ALX Oncology, BioCryst, Notable, Orum, Mendus, Zentalis, Schrodinger, Regeneron, Syros, Schrodinger, Tyme, Morphosys, Pharmaessentia, Acceleron Pharma, Epizyme, Adaptive Biotechnologies, ADC Therapeutics, Genmab, TG Therapuetics, Karyopharm, Loxo\/Lilly Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Novartis, Abbvie, Gilead, Syros, BioCryst, Abbvie, ALX Oncology, Kura, Geron and Celgene\/BMS, Leukemia Lymphoma SocietyStock or stock options: MedtronicOther financial or non-financial interests\/Institutional Research Funding: Celgene\/BMS, Abbvie, Astex, Pfizer, Kura, Medimmune\/AstraZeneca, Boehringer-Ingelheim, Incyte, Takeda, Novartis, Shattuck Labs, Geron, Foran, Prelude, Incyte, Kartos, and Aprea.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}